Kancera presents at Boston seminar April 27th, 2012.

2012-04-23

Kancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is “Lead Generation and Structure-Based Drug Design in Cancer Research”.

Chief Operating Officer Dr Martin Norin will describe how structural information and close interaction between clinical expertise and the drug discovery engine of iNovacia, Kancera’s wholly-owned daughter company, is of key importance in guiding the Kancera PFKFB3 and ROR programs.

Also presenting at the seminar is Professor Stefan Knapp, Group Leader of Chemical Biology at the Structural Genomics Consortium (SGC) in Oxford, UK, and Dr Charles Kung, Senior Scientist at Boston-based Agios Pharmaceuticals.

For more information about the event can be found at http://inovacia.se/boston-seminar.

About Kancera AB (publ)
Kancera is engaged in drug development that takes its start in new treatment concepts and ends with a pharmaceutical candidate. Kancera is currently developing medicines for the treatment of both leukemia and solid tumors that interfers with survival signaling and nutrient metabolism within the cancer cell. Kancera is also developing stem cell-based cancer models to study the effect of medicines before testing in humans. Kancera operates in Stockholm and employs approximately 20 people. The share is traded on the NASDAQ OMX First North and the number of shareholders is about one thousand. Remium AB is Certified Adviser to Kancera.

For additional information, please contact:
Thomas Olin, CEO: +46 735 20 40 01

Back